Effects of L-Carnitine and Ginkgo Biloba Extract (EG b 761) in Experimental Bleomycin-Induced Lung Fibrosis

Daba, Mohamed; Abdel-Aziz, Abdel-Aziz H.; Moustafa, Adel M.; Al-Majed, Abdulhakeem A.; Al‐Shabanah, Othman A.; El‐Kashef, Hassan A.

doi:10.1006/phrs.2002.0985

Cited by 47 publications

(29 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liu, 1992;J. Liu et al, 1993), Ginkgo biloba (Daba et al, 2002;Iraz et al, 2006), Moxibustion (R. Li et al, 2005), Fufang (Kong et al, 2005) etc. ), Immunosuppressants (Cyclosporin-A (Lossos, Or, Goldstein, Conner, & Breuer, 1996), Rapamycin analogue SDZ RAD (Simler et al, 2002)), Corticosteroids (Dexamethasone (F. Chen et al, 2006;Dik et al, 2003;H.…”

Section: Drug Intervention Studies In the Bleomycin Modelmentioning

confidence: 99%

The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Moeller

Ask

Warburton

et al. 2008

The International Journal of Biochemistry & Cell Biology

827

724

View full text Add to dashboard Cite

Different animal models of pulmonary fibrosis have been developed to investigate potential therapies for idiopathic pulmonary fibrosis (IPF). The most common is the bleomycin model in rodents (mouse, rat and hamster). Over the years, numerous agents have been shown to inhibit fibrosis in this model. However, to date none of these compounds are used in the clinical management of IPF and none has shown a comparable antifibrotic effect in humans. We performed a systematic review of publications on drug efficacy studies in the bleomycin model to evaluate the value of this model regarding transferability to clinical use. Between 1980 and 2006 we identified 246 experimental studies describing beneficial antifibrotic compounds in the bleomycin model. In 221 of the studies we found enough details about the timing of drug application to allow inter-study comparison. 211 of those used a preventive regimen (drug given ≤ day 7 after last bleomycin application), only 10 were therapeutic trials (> 7 days after last bleomycin application). It is critical to distinguish between drugs interfering with the inflammatory and early fibrogenic response from those preventing progression of fibrosis, the latter likely much more meaningful for clinical application. All potential antifibrotic compounds should be evaluated in the phase of established fibrosis rather than in the early period of bleomycin-induced inflammation for assessment of its antifibrotic properties. Further care should be taken in extrapolation of drugs successfully tested in the bleomycin model due to partial reversibility of bleomycin induced fibrosis over time. The use of alternative and more robust animal models, which better reflect human IPF, is warranted.

show abstract

Section: Drug Intervention Studies In the Bleomycin Modelmentioning

confidence: 99%

The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Moeller

Ask

Warburton

et al. 2008

The International Journal of Biochemistry & Cell Biology

827

724

View full text Add to dashboard Cite

show abstract

“…Subsequently, the lung/body weight ratio was determined. Homogenization was carried out in ice-cold KCl (1.15%, pH 7.4) to yield 10% w/v tissue homogenates (Daba et al, 2002) and the following biochemical parameters were assessed.…”

Section: Preparation Of Lung Homogenatementioning

confidence: 99%

Modulation of cyclophosphamide-induced early lung injury by allicin

Ashry

Gameil

Suddеk

2013

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: Cyclophosphamide (CP) causes lung injury in rats through its ability to generate free radicals with subsequent epithelial and endothelial cell damage. Objective: This study was conducted to assess whether allicin can ameliorate CP-induced early lung injury in rats. Materials and methods: Male Sprague Dawely rats were divided into four groups. Group I was the control group. Group II received allicin (50 mg/kg/d, p.o.) for 14 consecutive days. Group III was injected once with CP (150 mg/kg, i.p.). Group IV received allicin for seven consecutive days, before and after CP injection (150 mg/kg, i.p.). The parameters of study were serum biomarkers, lung tissue antioxidant profile and histopathological changes in lung tissue. Results: A single intraperitoneal injection of CP markedly altered the levels of several biomarkers in lung homogenates. Significant increases in lung content of lipid hydroperoxides were seen that paralleled the decreased levels of total reduced glutathione. Superoxide dismutase activity (SOD) was significantly increased. CP increased the level of serum biomarkers; total protein, lactate dehydrogenase (LDH) and tumor necrosis factor-alpha (TNF-a). Pretreatment of rats daily with oral allicin seven days prior to and seven days after CP inject significantly inhibited the development of lung injury, prevented the alterations in lung and serum biomarkers associated with inflammatory reactions, with less lipid peroxidation (LP) and restoration of antioxidants. Moreover, allicin attenuated the secretion of proinflammatory cytokine, TNF-a expression in rat serum. In addition, allicin effectively blunted CP-induced histopathological changes in lung tissue. Discussion and conclusion: Our results suggest that allicin is efficient in blunting CP-induced pulmonary damage.

show abstract

“…In addition, lazaroids are protective against bleomycin-induced lung fibrosis in rats (49,132). A number of natural products that contain polyphenolic compounds, such as Ginko biloba extracts and curcumin, have been found to suppress lung oxidative stress and fibrosis in rats treated with bleomycin (48,67,93,152,207).…”

Section: Fibrogenic Drugs Antioxidants and Oxidative Stressmentioning

confidence: 99%

Antioxidants as Potential Therapeutics for Lung Fibrosis

Day

2008

Antioxidants & Redox Signaling

124

View full text Add to dashboard Cite

Interstitial lung disease encompasses a large group of chronic lung disorders associated with excessive tissue remodeling, scarring, and fibrosis. The evidence of a redox imbalance in lung fibrosis is substantial, and the rationale for testing antioxidants as potential new therapeutics for lung fibrosis is appealing. Current animal models of lung fibrosis have clear involvement of ROS in their pathogenesis. New classes of antioxidant agents divided into catalytic antioxidant mimetics and antioxidant scavengers are being developed. The catalytic antioxidant class is based on endogenous antioxidant enzymes and includes the manganese-containing macrocyclics, porphyrins, salens, and the non-metal-containing nitroxides. The antioxidant scavenging class is based on endogenous antioxidant molecules and includes the vitamin E analogues, thiols, lazaroids, and polyphenolic agents. Numerous studies have shown oxidative stress to be associated with many interstitial lung diseases and that these agents are effective in attenuating fibroproliferative responses in the lung of animals and humans.

show abstract

Effects of L-Carnitine and Ginkgo Biloba Extract (EG b 761) in Experimental Bleomycin-Induced Lung Fibrosis

Cited by 47 publications

References 41 publications

The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Modulation of cyclophosphamide-induced early lung injury by allicin

Antioxidants as Potential Therapeutics for Lung Fibrosis

Contact Info

Product

Resources

About